Grufity logoGrufity logo

Albireo Pharma Inc Stock Research

ALBO

44.07USD+0.12(+0.27%)Market Closed

Market Summary

USD44.07+0.12
Market Closed
0.27%

ALBO Alerts

ALBO Stock Price

ALBO RSI Chart

ALBO Valuation

Market Cap

911.9M

Price/Earnings (Trailing)

-6.95

Price/Sales (Trailing)

15.89

EV/EBITDA

-4.57

Price/Free Cashflow

-7.84

ALBO Price/Sales (Trailing)

ALBO Profitability

Operating Margin

95.56%

EBT Margin

-263.46%

Return on Equity

-131.05%

Return on Assets

-40.83%

Free Cashflow Yield

-12.75%

ALBO Fundamentals

ALBO Revenue

Revenue (TTM)

57.4M

Revenue Y/Y

168.34%

Revenue Q/Q

19.81%

ALBO Earnings

Earnings (TTM)

-131.1M

Earnings Y/Y

-166.22%

Earnings Q/Q

5.38%

Price Action

52 Week Range

16.0244.40
(Low)(High)

Last 7 days

0.6%

Last 30 days

123.6%

Last 90 days

107.9%

Trailing 12 Months

71.6%

ALBO Financial Health

Current Ratio

6.32

ALBO Investor Care

Shares Dilution (1Y)

7.44%

Diluted EPS (TTM)

-6.72

Peers (Alternatives to Albireo Pharma)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
350.6B
1.2B
18.44% 28.04%
-166.6
280.55
17.64% -57.08%
259.1B
57.8B
-9.83% 10.63%
19.32
4.48
4.80% 77.95%
82.5B
8.7B
12.49% 40.85%
25.2
9.48
22.03% 50.41%
79.4B
15.0B
4.18% 22.03%
14.79
5.14
21.25% -23.23%
28.5B
960.9M
-0.11% 81.92%
-24.07
29.61
28.24% -41.08%
11.8B
1.9B
-5.00% 33.05%
16.73
6.36
12.37% 52.98%
10.8B
876.0M
-2.75% 83.75%
-15.06
12.31
35.70% -47.34%
MID-CAP
5.0B
504.0K
6.89% 417.98%
-18.07
2.5K
-66.53% -15.89%
3.1B
343.4M
0.46% -32.04%
-4.52
8.92
-4.50% -90.69%
3.1B
-
26.46% -50.77%
-4.14
917.1
- -52.72%
2.9B
272.3M
13.28% -31.85%
-3.98
10.5
-18.36% -74.56%
SMALL-CAP
1.6B
191.8M
-14.40% 192.28%
24.14
8.42
43.59% 60.82%
352.8M
93.0M
0.88% -49.25%
-1.85
3.79
-19.83% -30.37%
18.1M
-
32.75% -64.96%
-0.43
19.11
-77.61% 5.14%
4.0M
-
-5.44% 44.99%
-0.01
63.29
26.15% -23.38%

Financials for Albireo Pharma

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue12.0%57,391,00051,223,00045,445,00040,579,00010,774,000
Gross Profit229.7%39,223,00011,898,000---
Operating Expenses0.9%178,947,000177,303,000167,354,000162,708,000144,167,000
  S&GA Expenses3.9%78,763,00075,811,00071,151,00069,569,00063,983,000
  R&D Expenses2.6%88,705,00086,476,00084,482,00082,522,00081,970,000
EBITDA-347.7%-150,771,000.00-33,679,000.00-33,756,000.00--
EBITDA Margin-254.5%-2.63-0.74-0.83--
Earnings Before Taxes-162.1%-151,200,000.00243,500,000---
EBT Margin-251.8%-2.63-0.75-0.84--
Net Income-261.7%-131,145,000.00-36,259,000.00-32,731,000.00-34,030,000.00-47,867,000.00
Net Income Margin-222.8%-2.29-0.71-0.72-0.84-
Free Cahsflow-1.8%-116,282,000.00-114,281,000.00-108,813,333.33-108,024,000.00-
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets40.3%321229261302296
  Current Assets22.0%239196229269272
    Cash Equivalents22.9%222181217248263
  Inventory50.2%32200
  Net PPE-6.1%11111
  Goodwill0%1717171717
Liabilities91.7%221115113126115
  Current Liabilities-13.2%3844324533
Shareholder's Equity-12.0%100114148176182
  Retained Earnings-9.9%-421.03-383.23-343.28-300.85-289.89
  Additional Paid-In Capital5.0%513489483475472
Shares Outstanding5.6%2120201919
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-1.9%-115.32-113.17-108.25-107.56-121.86
  Share Based Compensation-19.2%1316161618
Cashflow From Investing-100.9%-0.96102137103206
Cashflow From Financing1650.8%1287733
  Buy Backs-75.0%01---

Risks for ALBO

What is the probability of a big loss on ALBO?

98.1%


Probability that Albireo Pharma stock will be more than 20% underwater in next one year

80%


Probability that Albireo Pharma stock will be more than 30% underwater in next one year.

63.9%


Probability that Albireo Pharma stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ALBO drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Albireo Pharma was unfortunately bought at previous high price.

Drawdowns

Returns for ALBO

Cumulative Returns on ALBO

-6.2%


10-Year Cumulative Returns

28.9%


7-Year Cumulative Returns

3.7%


5-Year Cumulative Returns

22%


3-Year Cumulative Returns

What are the long-term rolling returns for ALBO?

FIve years rolling returns for Albireo Pharma.

Annualized Returns

Which funds bought or sold ALBO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-01-25
Lindbrook Capital, LLC
reduced
-41.08
-5,010
8,990
-%
2023-01-24
NATIONAL BANK OF CANADA /FI/
unchanged
-
123
4,123
-%
2023-01-23
Sargent Bickham Lagudis LLC
unchanged
-
483
6,483
-%
2023-01-23
Allspring Global Investments Holdings, LLC
reduced
-39.02
-9,390
21,610
-%
2023-01-20
Chicago Capital, LLC
added
21.68
7,764,280
29,443,300
1.63%
2023-01-13
Allworth Financial LP
added
408.33
1,318
1,318
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-0.49
-13,000
425,000
-%
2022-11-17
M&T Bank Corp
added
17.03
60,000
484,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
sold off
-100
-2,000
-
-%
2022-11-16
BNP PARIBAS ARBITRAGE, SNC
added
112.86
138,812
267,942
-%

1–10 of 42

Latest Funds Activity

Are funds buying ALBO calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own ALBO
No. of Funds

Albireo Pharma News

Stocks Register

Albireo Pharma Inc. (ALBO) Has A Gold Mine On Its Hands.

Stocks Register,
24 hours ago

GuruFocus.com

ALBIREO PHARMA INVESTOR ALERT.

GuruFocus.com,
4 days ago

Digital Journal

Genetic Engineering & Biotechnology News

StockWatch: Shares Double for Targets of 3 Buyout Deals ....

Genetic Engineering & Biotechnology News,
16 days ago

Investing.com Australia

Schedule 13G FIlings of Albireo Pharma

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jan 23, 2023
chicago capital, llc
6.6%
1,362,484
SC 13G
Oct 03, 2022
deep track capital, lp
5.46%
1,124,421
SC 13G
Sep 26, 2022
tang capital partners lp
5.6%
1,099,516
SC 13G
Mar 07, 2022
chicago capital, llc
5.1%
971,885
SC 13G
Feb 14, 2022
federated hermes, inc.
12.23%
2,358,624
SC 13G/A
Feb 14, 2022
perceptive advisors llc
12.2%
2,360,139
SC 13G/A
Feb 09, 2022
state street corp
5.15%
992,832
SC 13G
Feb 03, 2022
blackrock inc.
6.1%
1,168,783
SC 13G/A
Feb 16, 2021
perceptive advisors llc
12.4%
2,360,139
SC 13G/A
Feb 16, 2021
arrowmark colorado holdings llc
3.9%
751,495
SC 13G/A

ALBO Fair Value

Recent SEC filings of Albireo Pharma

View All Filings
Date Filed Form Type Document
Jan 25, 2023
4
Insider Trading
Jan 25, 2023
4
Insider Trading
Jan 25, 2023
4
Insider Trading
Jan 25, 2023
4
Insider Trading
Jan 25, 2023
4
Insider Trading
Jan 25, 2023
4
Insider Trading
Jan 25, 2023
4
Insider Trading
Jan 25, 2023
4
Insider Trading
Jan 23, 2023
SC 13G
Major Ownership Report
Jan 23, 2023
SC 14D9
SC 14D9

Latest Insider Trading transactions for ALBO

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-01-23
Cooper Ronald Harold Wilfred
sold
-46,296.6
43.8
-1,057
president and ceo
2023-01-23
Carter Martha J.
sold
-5,256
43.8
-120
chief regulatory officer
2023-01-23
Harford Simon N.R.
sold
-4,467.6
43.8
-102
cfo and treasurer
2023-01-23
Stephenson Pamela
sold
-4,467.6
43.8
-102
chief commercial officer
2023-01-23
Duncan Jason
sold
-9,986.4
43.8
-228
chief legal officer and gc
2023-01-23
Graham Michelle
sold
-4,467.6
43.8
-102
chief human resources officer
2023-01-23
Mattsson Jan
sold
-8,628.6
43.8
-197
chief scientific officer
2023-01-19
Carter Martha J.
acquired
-
-
55,000
chief regulatory officer
2023-01-19
Duncan Jason
sold
-41,182.3
43.9044
-938
chief legal officer and gc
2023-01-19
STRECK PAUL
acquired
-
-
55,000
chief medical officer

1–10 of 50

Ronald H. W. Cooper
130
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

ALBO Income Statement

2022-09-30
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue:    
Revenue$ 9,832$ 3,664$ 24,870$ 8,058
Cost and operating expenses:    
Cost of product revenue6124311,622431
Research and development23,31221,08368,10361,920
Selling, general and administrative20,56417,61259,01949,825
Other operating expense, net13,7197,5447,873
Total cost and operating expenses44,48942,845136,288120,049
Operating loss(34,657)(39,181)(111,418)(111,991)
Other (loss) income:    
Gain from sale of priority review voucher, net of transaction costs 103,387 103,387
Loss on extinguishment of debt(613) (613) 
Interest expense, net(2,530)(3,331)(8,152)(10,675)
Net (loss) income before income taxes(37,800)60,875(120,183)(19,279)
Provision for income taxes03,78903,789
Net (loss) income$ (37,800)$ 57,086$ (120,183)$ (23,068)
Net (loss) income per share attributable to holders of common stock:    
Basic (in dollars per share)$ (1.92)$ 2.96$ (6.15)$ (1.20)
Diluted (in dollars per share)$ (1.92)$ 2.90$ (6.15)$ (1.20)
Weighted-average common shares outstanding:    
Basic (in shares)19,655,35019,258,90519,541,04419,197,536
Diluted (in shares)19,655,35019,651,24319,541,04419,197,536
Product    
Revenue:    
Revenue$ 7,543$ 1,060$ 18,090$ 1,060
Royalty    
Revenue:    
Revenue$ 2,289$ 2,604$ 6,780$ 6,998

ALBO Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 222,476$ 248,107
Accounts receivable, net2,0293,272
Inventory3,149194
Prepaid expenses8,5165,261
Other current assets2,66612,096
Total current assets238,836268,930
Restricted cash50,000 
Property and equipment, net1,303668
Goodwill17,26017,260
Other assets13,82315,193
Total assets321,222302,051
Current liabilities:  
Accounts payable6,9506,516
Accrued expenses25,36535,951
Other current liabilities5,5042,880
Total current liabilities37,81945,347
Liability related to sale of future royalties62,05360,132
Revenue interest liability, net111,644 
Note payable, net of discount 10,004
Other long-term liabilities9,63510,960
Total liabilities221,151126,443
Stockholders' Equity:  
Preferred stock, $0.01 par value per share - 50,000,000 shares authorized at September 30, 2022 and December 31, 2021; 0 and 0 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively
Common stock, $0.01 par value per share - 60,000,000 shares authorized at September 30, 2022 and December 31, 2021; 20,700,458 and 20,692,698 shares issued and outstanding at September 30, 2022, respectively, and 19,304,312 and 19,296,552 shares issued and outstanding at December 31, 2021, respectively207193
Additional paid-in capital512,915475,390
Accumulated other comprehensive income8,2121,105
Accumulated deficit(421,033)(300,850)
Treasury stock at cost, 7,760 shares at September 30, 2022 and December 31 2021, respectively(230)(230)
Total stockholders' equity100,071175,608
Total liabilities and stockholders' equity$ 321,222$ 302,051